Naslov
Endocan - Novel biomarker in patients with acute heart failure?

Autori
Potočnjak, Ines ; Trbušić, Matias ; Dokoza Terešak, Sanda ; Pregartner, Gudrun ; Frank, Saša ; Degoricija, Vesna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Journal of Heart Failure / Metra, Marco - Pariz : European Society of Cardiology (ESC), 2017, 33-33

Skup
Heart Failure 2017 and the 4th World Congress on Acute Heart Failure

Mjesto i datum
Pariz, Francuska, 29.04.2017. - 02.05.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
endocan ; heart failure ; biomarker

Sažetak
On behalf of: AHF study group. Background: Endocan is known as an endothelial cell- specific molecule 1 (ESM-1), exhibiting anti- inflammatory properties. It is a proteoglycan with a chondroitin/dermatan sulfate chain. Its elevated level is connected with endothelial activation, inflammation and carcinogenesis. According to the manufacturer, the normal range is 0.3-3ng/mL. To our knowledge, endocan has not been previously investigated in Acute heart failure (AHF) patients (pts). Purpose: The aim of this study was to investigate the impact of sex, age, ejection fraction (EF), NYHA classification, CRP and blood pressure (BP) on endocan values in AHF pts. Methods: The study was performed as a prospective, non- interventional, single- center observational study from November 2013 to February 2015 in the University hospital centre, Croatia. There were 80 pts with AHF included. Complete analysis was performed for 75 pts since five of them had high endocan values (≥20ng/ml), which were considered unmeasurable. For analysis, ELISA kit was used to detect and quantify human Endocan/ESM-1 in serum. Pts were grouped according to demographic and laboratory parameters, with cut-off values of 5mg/L for CRP, ≤40%, 41-49%, and ≥50 for EF, and 140/90mmHg for BP. Pts were classified and treated according to ESC guidelines. The study was conform to the principles of the Declaration of Helsinki of the World Medical Association. Differences between the groups were determined by the non- parametric Mann- Whitney U or Kruskal-Wallis test. Results will be shown as median and minimum and maximum. The analyses were conducted using R version 3.3.1. Results: The median endocan concentration was 4.8ng/ml (1.3- 15.2). Endocan was not significantly different between the sexes [4.8ng/ml (1.3-15.2) for men, 4.4ng/ml (1.5- 14.7) for women ; p=0.848]. Pts ≤75 years of age had a median value of 3.2ng/ml (1.6-14.7) and pts >75 had 5.2ng/ml (1.3-15.2) (p=0.054). The median endocan value in NYHA classification groups 2 or 3 was 4.8ng/ml (1.3- 15.2) and 4.6ng/ml (1.5- 14.7) in group 4 (p=0.630). In pts with normal CRP (≤5), median endocan was 4.3ng/ml (1.6-14.7) and with elevated CRP (>5) was 5.2 ng/ml (1.3- 15.2) (p=0.610). According to EF, the median endocan value for pts with decreased EF ≤40% was 5.0ng/ml (1.5-14.7), with an EF 41-49% was 4.8ng/ml (1.3-14.3) and with EF ≥50 was 4.4ng/ml (1.6-15.2) (p=0.625). Pts with a systolic BP of <140mmHg had a median endocan value of 5.5ng/ml (1.3-15.2) whereas with ≥140mmHg had 4.2ng/ml (1.6-14.7) (p=0.148). For diastolic BP, pts with <90mmHg had a median endocan value of 4.8ng/ml (1.3- 15.2) whereas with ≥90mmHg had 4.4ng/ml (1.6- 14.7) (p=0.595). Conclusion: To our knowledge this was the first research of endocan in AHF pts. According to the results of this study on 75 pts, endocan was higher in our AHF pts compared to previously measured values in healthy volunteer, but did not differ significantly between groups according to sex, age, EF, NYHA classification, CRP and BP.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA